The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is a well-known signaling pathway involved in cancer development and progression, including LUSC [6], indicating that this pathway may be a potential therapeutic target for LUSC patients. The gene discussed is AKT1; the disease is cancer.